Skip to main content

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Pollyea, DA; Altman, JK; Assi, R; Bixby, D; Fathi, AT; Foran, JM; Gojo, I; Hall, AC; Jonas, BA; Kishtagari, A; Lancet, J; Maness, L; Mims, A ...
Published in: J Natl Compr Canc Netw
May 2023

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

May 2023

Volume

21

Issue

5

Start / End Page

503 / 513

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Oncology & Carcinogenesis
  • Medical Oncology
  • Leukemia, Myeloid, Acute
  • Humans
  • Hematologic Neoplasms
  • Dendritic Cells
  • Adult
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pollyea, D. A., Altman, J. K., Assi, R., Bixby, D., Fathi, A. T., Foran, J. M., … Stehman, K. (2023). Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(5), 503–513. https://doi.org/10.6004/jnccn.2023.0025
Pollyea, Daniel A., Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, et al. “Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 21, no. 5 (May 2023): 503–13. https://doi.org/10.6004/jnccn.2023.0025.
Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 May;21(5):503–13.
Pollyea, Daniel A., et al. “Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 21, no. 5, May 2023, pp. 503–13. Pubmed, doi:10.6004/jnccn.2023.0025.
Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival M-E, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 May;21(5):503–513.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

May 2023

Volume

21

Issue

5

Start / End Page

503 / 513

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Oncology & Carcinogenesis
  • Medical Oncology
  • Leukemia, Myeloid, Acute
  • Humans
  • Hematologic Neoplasms
  • Dendritic Cells
  • Adult
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis